Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that ...

December 2024 seems to be the month of skepticism for Biogen Inc ( NASDAQ:BIIB ), as this biotechnology company focusing on neurological and neurodegenerative diseases has received multiple downgrades ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

Seoul Asan Medical Center said it started prescribing the early Alzheimer's disease drug "Leqembi" (generic name lecanemab) ...

How new science is finding new drugs and new approaches to fight Alzheimer's Disease, the number seven killer in America.

Medicare Part B covers Leqembi for people with early Alzheimer's or mild cognitive impairment. Learn more about Leqembi and Medicare coverage here.

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...